Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107
ConclusionXP as first-line therapy is effective and well tolerated by patients with HER2-negative AGC.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Anemia | Anorexia | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Eating Disorders & Weight Management | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Japan Health | Study | Toxicology | Xeloda